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Abstract
The designation of "early" IgA nephropathy is often used in patients with normal renal function, no
or mild proteinuria, and absence of other features, but the term is in fact poorly defined judging
from the varying norms adopted. Even with stringent clinical criteria used to characterize clinical
early IgA nephropathy, these may not be correlated with the prediction of disease outcome, nor
with the severity of renal lesions. Due to such limitations, the clinical reference to early IgA
nephropathy represents more a concept than an accurate measure. The histological definition of
"early" IgA nephropathy appears to be different as the grading of biopsy permits one to segregate
by semiquantitation patients with early renal lesion and very low risk of progression. This review
puts the emphasis on the morphologic definition of early IgA nephropathy based on objective criteria,
and on its practical consequences. The clinical implications include a better patient selection in
therapy, and the potential to enhance results of treatment as well as for the appraisal of clinical
trials. We also suggest that all patients suspected for IgA nephropathy, including those in early
clinical stage should undergo renal biopsy because the information yielded are critical to the
management and therapy.
Key words: Angiotensin converting enzyme inhibitor (ACEI), Berger's disease, Disease progression, Early IgA
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INTRODUCTION
Since the recognition of primary IgA nephropathy as a
distinct entity, and in spite of intensive clinical and
laboratory investigations, the pathogenesis of such
nephritis remains largely obscure (1-4). While
predominant IgA-containing immune complexes in the
mesangium characterize its renal lesions, the primary
events leading to their formation and glomerular
distribution are undetermined (3-5). It has been argued
that the initial primary defect resides in the IgA molecule
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itself, and immune complex represents only the
consequence (3,6). As a result, the management of these
patients is confined to nonspecific supportive therapy,
aiming to slow down the development of the disease (5,
7-10).
Although such a nondisease-specific treatment approach
is empirical, it has resulted in some successes,
presumably various drugs may have interfered with some
secondary disease mechanisms (8-10). It is also
increasingly clear that the detection of risk factors
associated with disease progression such as hypertension,
heavy proteinuria or impaired renal function is of utmost
importance. Even though these factors are nondisease
specific, they can be modified by symptomatic treatment
(7-10). However, while such useful treatment applies to
carefully selected high-risk patients, currently there is
no consensus on the optimal therapeutic approach in
patients at an early stage or at the onset of disease (9-
13). Corticosteroid therapy, which has shown mixed
results in unselected patients with IgA nephropathy,
appears to be more effective with patients having early
disease (9,10,12,14). Furthermore, there is accumulating
evidence that angiotensin converting enzyme inhibitor
(ACEI) reduces the rate of renal function deterioration
in patients with mild renal impairment and significant
proteinuria in excess of 1 g per day (10,15,16). One of
the important options in the treatment approach of IgA
nephropathy is the early detection of disease progression,
and the prompt management of risk factors associated
with the progression (7-10). However, two related factors
have caused difficulties in selecting patients for clinical
trials, and in assessing their results.  These include the
inability to identify the onset of the disease, and the
unpredictable clinical course, and consequently to
determine when therapy should be initiated (9,10,12,13,
17).
This review discusses the determination of early IgA
nephropathy, based on the two recent local studies on
histological grading (18,19). Such a grading system
underscores the importance of chronic renal lesions,
which are most correlated with the slowly progressive
behavior in many patients with IgA nephropathy (13,
18-20).
Why does the clinical designation of "early"
IgA nephropathy remain a concept?
The clinical designation of "early" IgA nephropathy
generally refers to patients with a normal renal function,
with no or minimal proteinuria, and absence of other
manifestations such as hypertension, irrespective of the
type of hematuria (14,18-20). But in fact, the norms used
in the clinical reference of early disease are varying, and
often depend upon the degree of proteinuria or the serum
level of creatinine (9,13,14,18,19). Although stringent
criteria are adopted to identify early clinical IgA
nephropathy, and despite their trivial clinical
manifestations, we confirmed others' observations that
such criteria may not predict the renal outcome, nor the
absence or presence of renal lesions (9,14,19,20).
Because of such a limitation, the clinical reference to
early IgA nephropathy represents more a concept than
an objective measure. However, such a practical
designation of "early" nephropathy permits one to make
therapeutic decision, in particular to withhold therapy
based on the assumption that trivial clinical symptoms
correspond to a mild form of disease, not requiring
medical attention until evidences for disease progression
appear (8-12). This inaccurate clinical label of early IgA
nephropathy is further complicated by the uncertainty at
that stage on who will show disease progression, and
thus the inability to decide when to initiate therapy (9,
10,12,13,17).
Histological grading and morphologic
determination of early IgA nephropathy
The importance of mesangial sclerosis cannot be
emphasized more, because it represents the most
prevalent renal lesions associated with IgA-containing
complexes, and the most accountable for the protracted
and progressive course in many patients with IgA
nephropathy (3,4,13,18). At the early stage of renal
injury, there must be a point where mesangial sclerosis
is initiated, but what follows the onset of such initial
lesion is uncertain. In patients with progressive disease
the cumulative effects of these irreversible sclerosing
Table 1.  Chronicity-based grading of IgA nephropathy.
Glomerular Grading
GG 1 For a mean % of sclerosis per glomerulus between
  0% and < 25%
GG 1a For a mean % of sclerosis per glomerulus between
  0% and  <10%
GG 1b For a mean % of sclerosis per glomerulus between
  10% and < 25%
GG 2 For a mean % of sclerosis per glomerulus between
  25% and < 50%
GG 3 For a mean % of sclerosis per glomerulus equal or
  over 50%
Tubulointerstitial Grading
TIG 1 Tubular atrophy and interstitial fibrosis were absent
  or < 5%
TIG 2 Tubular atrophy and interstitial fibrosis in a 5% to
  < 50% area
TIG 3 Tubular atrophy and interstitial fibrosis in an area
  equal or over 50%
Hyaline arteriolosclerosis - present or absent
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processes lead to varying degree of glomerular distortion
and obliteration (13,18). In many other patients, it is
possible that initiated lesions may remain static or even
be regressive, but supporting evidence for such an
evolution are scarce and patients with minor symptoms
rarely have a repeated biopsy (13,21). While the
histological grading has been correlated with clinical
features such as proteinuria, hypertension, and impaired
renal function, it is important to keep in mind that clinical
early disease with trivial symptoms does not necessarily
correspond to the absence of renal lesion (13,18,19).
The chronicity-based grading of IgA nephropathy used
at the Prince of Wales Hospital (Table 1) has correlated
all three histological parameters with serum creatinine,
proteinuria, and hypertension at the time of biopsy, and
with renal survival on a median follow-up of 10 years
(18). Such a grading system will provide two pieces of
important information on the individual biopsy: one is
the relative risk for renal survival based glomerular,
tubular and arteriolar grades, irrespective of the renal
function or the stage of the disease. The second applies
to patients with clinical early disease, and relates to the
relative risk associated with disease progression, as
determined by occurrence of hypertension, proteinuria
and impairment of renal function on follow-up (18,19).
Not uncommonly, the biopsy of a single patient displays
the wide spectrum of sclerosing lesions evolving from a
normal glomerulus through intermediate glomerular
distortion and finally to obsolescence, and thus the
representation of a microcosm on the natural history of
the glomerular injury in IgA nephropathy, which may
span over several decades (Fig. 1).
It is interesting that in patients with a normal serum
creatinine, and at a relatively early disease stage, the
glomerular grade (GG) is the only independent predictor
of renal survival, which appears only logical when the
initial mechanisms of renal injury take place in the
glomerulus (13,18). In contrast, the tubulointerstitial
grade (TIG) has been shown to be a stronger predictor
of renal outcome as the disease advances (Fig. 2) (13,
18,21). We attribute such an observation to the role of
"magnifier" played by the tubules whereby an
obsolescent glomerulus, will result in the atrophy and
Figure 1.  A., Normal appearing glomerulus, (B) mild mesangial sclerosis with an intact tufts architecture scored
as 0%, (C) segmental sclerosis with capillary collapse and distortion of tufts architecture, scored as 25%, and (D)
coalescent segmental sclerosis progressing towards global sclerosis or obsolescence. Periodic Acid-Silver
Methenamine, counterstained with Hematoxylin & Eosin, all x240.
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collapse of the same remaining nephron, which will then
appear on histological section as a cluster of 10 to 20
atrophic tubules in a larger and more conspicuous area.
In patients with clinical early IgA nephropathy selected
by stringent criteria, including a serum creatinine of 120
µmol/L or less, a proteinuria of 0.4 g/day or less, and
normal blood pressure, we found that while most of these
patients demonstrated low-grade glomerular lesions
(GG1a and GG1b), nearly half of those with GG1b
experienced disease progression, as reflected by the
subsequent occurrence of proteinuria over 0.5 g/day, of
hypertension, and of impaired renal function with a serum
creatinine over 130 µmol/L (18,19). More importantly,
most patients with GG1a had no evidence of disease
progression on a long term follow-up, and they
constituted the group, which makes genuine early IgA
nephropathy a reality (19).
The other important facet of early IgA nephropathy is
the relatively early and common development of
hypertension in patients with GG1b, in which case a mean
sclerosis per glomerulus starts at 10% (19). Therefore
hypertension not only complicates IgA nephropathy at
its early stage, but also appears to be an important
nonimmunologic factor promoting the disease. Such an
observation makes it attractive to explain the beneficial
role of ACEI in slowing down disease progression, and
it would be logical to try ACEI in patients with subclasses
GG1b and GG2, which opens new directions for clinical
trials (15,16,19). However, this would require extension
of the indication of renal biopsy to all clinically suspected
early IgA nephropathy patients.
Limitations of these recent studies on the histological
grading of IgA nephropathy
1. Although the GG1a determines patients with a very
low risk of clinical disease progression examined over
a reasonably long median 10-year follow-up, the
utmost significance of this specific category can only
be validated by demonstrating a genuine absence of
morphologic progression by a repeated renal biopsy.
2. Similarly, in patients with GG1b and GG2, the
correlation of clinical disease progression with
deterioration of renal lesions can only be permitted
by a repeated biopsy. Previous experience with repeat
biopsy in IgA nephropathy was from unselected
patients, often with more advanced disease.  It revealed
that renal lesions were static in a few patients, but had
worsened in many, and cases with regression were so
rare that they remain to be confirmed (13,21).
3. It is possible that a median follow-up longer than the
10-year from our study would enhance the accuracy
and the predictive strength in disease progression.
However, for such a protracted condition, the
assessment of renal survival in patients with early IgA
nephropathy requires a much longer follow-up period.
4. The chronicity-based histological grading for IgA
nephropathy relates to adults, and the validity of such
a grading system in pediatric patients and in Henoch-
Schonlein purpura, where acute lesions may be more
common, remain to be established.
SUMMARY AND PERSPECTIVES
Our recent histological grading of IgA nephropathy based
on chronic renal lesions over a relatively long follow-up
period has revived several important issues. It is
unequivocal that many patients follow a slow progressive
course, which can be predicted by both clinical and
pathological factors, but we now realize that such
prognostic features can appear at a much earlier stage,
and that the "point of no return" may set in much earlier
than perceived. Consequently, supportive therapy and
clinical trials must be considered when the renal lesions
are still reversible or when irreversible sclerosis are mild,
though it is difficult to determine the optimal time when
to intervene.
Figure 2.  A., Normal appearing glomerulus with intact tubules and
cortex (TIG 1), (B) mild mesangial sclerosis with focal tubular
atrophy and interstitial fibrosis (TIG 2), (C) extensive tubular loss
and atrophy (TIG 3), associated with increased glomerular
obsolescence. Periodic Acid-Silver Methenamine, counterstained
with Hematoxylin & Eosin, all x140.
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This article stresses on the distinction between clinical
and morphological features of early IgA nephropathy.
The objective histological criteria permit discrimination
of progressive from nonprogressive disease, and
recognition of genuine early disease. Clearly, the
morphologic definition of early IgA nephropathy now
appears far more accurate than the clinical estimation,
and transforms a concept into a reality. One important
implication is that this will enable one to time the onset
of the disease or to determine when therapeutic
intervention would be most effective. This review also
suggests that any patient suspected for IgA nephropathy
should undergo renal biopsy, not only for diagnosis and
assessment of prognosis, but for its potential role in the
patient management by enhancing treatment options,
clinical trials, and renal survival.
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